Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesRadiation Oncologyeocco Surface Radiation Therapy Coverage Update | …
    Ask Trek AI about this page
    CurrenteoccoPolicy N/A

    Surface Radiation Therapy for Treatment of Non-Melanoma Skin Cancer

    Customize your policy alerts

    Sign up for all eocco policy alerts

    Know when eocco releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity, prior authorization documentation, coding, and exclusions for use of surface radiation therapy (SRT) to treat superficial non-melanoma skin cancers (BCC and cSCC) for the payer's covered population.

    Policy Summary
    Payereocco
    PolicySurface Radiation Therapy for Treatment of Non-Melanoma Skin Cancer
    Policy CodePolicy N/A
    Change TypeAnnual review — no material changes
    Effective DateJul 9, 2026
    Last ReviewApr 22, 2026
    Next Review DateApr 22, 2026
    Key ActionSubmit prior authorization with clinical documentation (pathology, lesion characteristics, clinical rationale, decision-making and treatment plan).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1New policy (annual review)
    4Required clinical criteria elements

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    4SRT CPT/HCPCS codes listed
    1Planning/simulation units allowed

    Coverage Criteria

    Medical necessity

    Covered when ALL of the following are met

    SRT medical necessity criteria: 1. Tumor is superficial and localized without deep invasion or metastasis
    Histology: 2. Histology confirms basal cell carcinoma (BCC) or cutaneous squamous cell carcinoma (cSCC), including SCC in situ
    Surgery appropriateness or patient choice: 3. At least one of the following: (a) Surgery is not clinically appropriate; (b) Significant cosmetic or functional morbidity is expected with surgery; (c) Patient declines surgery after documentation that surgery was clinically appropriate but associated with significant morbidity or contraindications and after shared decision-making
    Risk stratification: 4. Tumor is low-risk or select high-risk per NCCN-based criteria (tumors limited by size or location without aggressive histology, perineural invasion, recurrence, or immunosuppression) — see Appendix A

    See Appendix A for risk features

    Treatment intent: 5. Treatment intent is definitive or adjuvant

    Not medically necessary / Contraindications

    Not medically necessary when ANY of the following apply

    First-line surgical candidates: a. Use of SRT as a first-line treatment option in surgical candidates who have access to standard excision or Mohs micrographic surgery (these surgical options are the preferred treatment for high-risk lesions)
    Advanced disease: b. Treatment of advanced basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)
    Contraindications: c. Contraindications including aggressive tumor histology or deep (>6 mm) tumor invasion, or bone or cartilage involvement; previously irradiated lesions or overlapping radiation fields; immunosuppressed patients (including solid organ transplant recipients) unless multidisciplinary review supports use due to lack of surgical alternatives>6 mm

    Previously irradiated or overlapping fields and immunosuppression are additional contraindications

    SRT is not medically necessary for lesions that meet any of the following exclusion criteria: previously irradiated lesions or overlapping radiation fields; aggressive tumor histology; deep invasion defined as > 6 mm; or involvement of bone or cartilage. Immunosuppressed patients (including solid organ transplant recipients) are also excluded unless a multidisciplinary review documents that surgical alternatives are not available and supports use of SRT.

    Surface radiation therapy is not medically necessary as a first-line treatment when the patient is a surgical candidate with access to standard excision or Mohs micrographic surgery, which are the preferred options for many lesions (particularly high-risk lesions). In addition, SRT is not medically necessary for the treatment of advanced basal cell carcinoma (BCC) or squamous cell carcinoma (SCC).

    Coding

    Covered CPT/HCPCS CodesCPTCovered
    77436Surface radiation therapy; superficial or orthovoltage, treatment planning and simulation-aided field setting.
    77437Surface radiation therapy; superficial, delivery, =150 kV, per fraction (eg, electronic brachytherapy).
    77438Surface radiation therapy; orthovoltage, delivery, >150-500 kV, per fraction.
    77439Surface radiation therapy; superficial or orthovoltage, image guidance, ultrasound for placement of radiation therapy fields for treatment of cutaneous tumors, per course of treatment (List separately in addition to code for primary procedure).
    Not covered CPT/HCPCS CodesCPTNot Covered
    No codes listed
    Applicable diagnosis codes (appendix incomplete)ICD-10
    No codes listed
    Depth of invasion — contraindication threshold (>6 mm)
    Depth of invasion threshold>6 mm — tumor invasion deeper than 6 mm is a contraindication to SRT
    Related contraindicationsBone or cartilage involvement — SRT not appropriate when underlying bone or cartilage is involved
    Aggressive histologyAggressive tumor histology is listed as a contraindication to SRT
    Previously irradiated sitesPreviously irradiated lesions or overlapping radiation fields are contraindications

    Provider Actions and Requirements

    Prior Authorization

    Prior authorization: submit clinical documentation

    Submit a prior authorization with clinical documentation to establish medical necessity for SRT, including pathology report, lesion characteristics, clinical rationale, decision-making, and the proposed treatment plan.

    • Pathology report confirming BCC or cSCC
    • Lesion characteristics (size, depth, location)
    • Clinical rationale and documented decision-making
    • Planned treatment intent and fields
    Step Therapy

    Preferred-first therapy: surgery preferred; SRT only if surgery inappropriate

    Use surgery (standard excision or Mohs) as the preferred first-line treatment; SRT is appropriate only when surgery is not clinically appropriate, would cause significant cosmetic or functional morbidity, or the patient declines surgery after documented shared decision-making.

    Background

    Nonmelanoma skin cancers (primarily basal cell carcinoma and cutaneous squamous cell carcinoma) commonly arise in sun-exposed sites and are often treated with surgery as the preferred first-line therapy. Surface radiation therapy (SRT) delivers low‑energy radiation to superficial cutaneous lesions and may be considered in selected situations, but it is generally reserved for patients who are not surgical candidates, for those who would incur significant cosmetic or functional morbidity from surgery, or when used for adjuvant or palliative intent. Use of SRT is restricted by specific contraindications and prior‑authorization requirements, and planning/simulation is limited to one unit per course of treatment.

    Definitions

    Surface radiation therapy (SRT) — definition and technical summary
    DefinitionSurface radiation therapy (SRT) is a form of low‑energy (typically kilovoltage range) radiation designed to treat superficial cutaneous lesions while limiting dose to deeper tissues.
    Typical useUsed to treat superficial nonmelanoma skin cancers (NMSC) — e.g., localized BCC and cSCC — when surgery is not appropriate or is declined after shared decision‑making.
    Clinical intentsCan be delivered with definitive intent, as adjuvant therapy (eg, for close/positive margins when further surgery is not feasible), or for palliation in selected advanced cases.
    Technical noteSRT employs low‑energy kilovoltage radiation to concentrate dose superficially and minimize deeper tissue exposure.
    Planning limitationPlanning and simulation for SRT are limited to one unit per course of treatment (planning/simulation services included).
    Policy Summary
    Payereocco
    PolicySurface Radiation Therapy for Treatment of Non-Melanoma Skin Cancer
    Policy CodePolicy N/A
    Change TypeAnnual review — no material changes
    Effective DateJul 9, 2026
    Last ReviewApr 22, 2026
    Next Review DateApr 22, 2026
    Key ActionSubmit prior authorization with clinical documentation (pathology, lesion characteristics, clinical rationale, decision-making and treatment plan).
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider Actions and RequirementsBackgroundDefinitions
  1. Surgery is preferred for high-risk lesions and when available
  2. SRT is reserved for patients who are not surgical candidates or who decline surgery after counseling
  3. Documentation Required

    Documentation required to establish medical necessity

    Include clinical documentation with the prior authorization that establishes medical necessity: pathology report, lesion characteristics, clinical rationale, decision-making, and the treatment plan.

    • Pathology confirming diagnosis
    • Lesion details (superficial/localized, size, depth, location)
    • Documentation of why surgery is not appropriate or was declined
    • Treatment intent (definitive or adjuvant) and planned fields
    Denial Risk

    Denial triggers: scenarios considered not medically necessary

    SRT will be considered not medically necessary for first-line treatment in surgical candidates with access to standard excision or Mohs, for treatment of advanced BCC/SCC, and when contraindications are present (eg, aggressive histology, deep invasion >6 mm, bone/cartilage involvement, previously irradiated/overlapping fields, or immunosuppression without multidisciplinary support).

    • First-line use in surgical candidates with access to excision or Mohs
    • Treatment of advanced BCC or SCC
    • Aggressive histology or tumor invasion >6 mm
    • Bone or cartilage involvement
    • Previously irradiated lesions or overlapping radiation fields
    • Immunosuppressed patients unless multidisciplinary review supports use
    Nonmelanoma skin cancer (NMSC) — scope (BCC and cSCC)
    Included tumor typesNonmelanoma skin cancer (NMSC) includes basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC).
    Common locationsNMSC lesions frequently occur in sun‑exposed areas, particularly the head and neck (eg, nose, ears, eyelids, lips).
    Primary managementSurgery (standard excision or Mohs) is generally the primary treatment approach for most low‑risk NMSC; SRT is reserved for selected cases.
    When SRT consideredSRT may be considered for appropriately selected superficial NMSC when surgery is contraindicated, not clinically appropriate, or declined after documented shared decision‑making.